Relmada Therapeutics, Inc.: Form 10-Q for the period ended Feb 28, 2014
Filed with the SEC on Apr 15, 2014 and accepted by EDGAR at Apr 15, 2014, 12:35 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-02-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-12-01 to 2014-02-28 | $682 | us-gaap:Revenues |
| Revenue | 6 months2013-09-01 to 2014-02-28 | $2.5k | us-gaap:Revenues |
| Cost of revenue | 3 months2013-12-01 to 2014-02-28 | $685 | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2013-09-01 to 2014-02-28 | $2.4k | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2013-12-01 to 2014-02-28 | −$3 | us-gaap:GrossProfit |
| Gross profit | 6 months2013-09-01 to 2014-02-28 | $161 | us-gaap:GrossProfit |
| Operating income | 3 months2013-12-01 to 2014-02-28 | −$3.1k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2013-09-01 to 2014-02-28 | −$17.5k | us-gaap:OperatingIncomeLoss |
| Net income | 6 months2013-09-01 to 2014-02-28 | −$17.5k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2013-12-01 to 2014-02-28 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2013-09-01 to 2014-02-28 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2013-09-01 to 2014-02-28 | −$12.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2014-02-28 | $2.6k | us-gaap:Cash |
| Current assets | At period end2014-02-28 | $8.8k | us-gaap:AssetsCurrent |
| Total assets | At period end2014-02-28 | $10.0k | us-gaap:Assets |
| Current liabilities | At period end2014-02-28 | $41.2k | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2014-02-28 | −$31.2k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001255294-14-000328. Last ingested by Listed: Oct 24, 2026, 15:13 ET. Listed shows no prices and gives no investment advice.